http://www.fpnotebook.com/
Clostridium difficile
Aka: Clostridium difficile, Pseudomembranous colitis, Pseudomembranous Enterocolitis
- See Also
- Diarrhea
- Infectious Diarrhea
- Chronic Diarrhea
- Epidemiology
- Dramatic increase in cases in last decade
- Pathophysiology
- Obligate, anaerobic, Gram Positive, spore-forming bacillus
- Causes Secretory Diarrhea via 2 toxins (A and B)
- New virulent strain: NAP1/B1/027
- Toxin A/B levels are >16 fold higher than other strains
- Produces binary toxin in addition to typical toxins A and B
- Higher rate of associated toxic Megacolon
- Sequence of infection
- Normal colonic bacteria disturbed (e.g. antibiotics)
- Exposure to C. difficile
- C. difficile is commensal in only 3% of patients
- C. difficile survives in hospital room >40 days
- Occurs in 50% of those hospitalized >4 weeks
- Colonization with Clostridium difficile
- Results in carrier state (asymptomatic) or
- Mild Diarrheal illness or
- Severe illness (Pseudomembranous colitis)
- Risk Factors
- Highest risk patients
- Elderly
- Debilitated patients
- Immunocompromised patients
- Cystic Fibrosis patients (high risk for fulminant infection)
- Acid suppression
- Proton Pump Inhibitors (e.g. Omeprazole)
- Highest risk as they raise gastric pH most significantly
- H2 Blockers (e.g. Ranitidine)
- Less risk than with Proton Pump Inhibitors
- Consider stopping indefinately following diagnosis of Clostridium difficile (due to higher risk of recurrence)
- Corticosteroid use
- Recent antibiotic use (especially last 7-10 days)
- General
- All antibiotics can cause C. difficile Diarrhea
- Broad-spectrum agents are highest risk
- Most common antibiotic causes
- Quinolones (e.g. Ciprofloxacin, Levofloxacin)
- Emerging as very common cause
- Ampicillin or Amoxicillin (most common cause in United States)
- Cephalosporins
- Clindamycin
- More common cause again since resurgence for MRSA management
- Less common antibiotic causes
- Macrolides (e.g. Erythromycin, Azithromycin)
- Tetracyclines antibiotics (e.g. Doxycycline)
- Sulfonamides (e.g. Bactrim)
- Trimethroprim
- Rare antibiotic causes
- Parenteral Aminoglycosides
- Metronidazole (used for treatment)
- Vancomycin (used for treatment)
- Symptoms
- Asymptomatic carrier state is common
- Megacolon may be present without Diarrhea
- Diarrhea (variably present)
- Timing
- Incubates for 2-7 days after colonization
- Most cases occur on days 4-9 of antibiotic course
- Onset <14 days after antibiotics in 96% of cases
- All cases occur within 3 months of antibiotics
- Olson (1994) Infect Control Hosp Epidemiol 15:371
- Characteristics
- Frequent, watery Bowel Movements to profuse Diarrhea up to 20-30 stools daily
- Mucus and occult blood often present
- Crampy Abdominal Pain
- Associated findings
- Fever
- Asymmetric oligoarticular large joint arthralgia
- Labs
- Hypoalbuminemia
- Complete Blood Count
- Leukocytosis variably present
- White Blood Cell count may be greater than 20,000
- White Blood Cell count greater than 30,000 is related to C. difficile in 25% of cases
- Radiology: Abdominal XRay
- Dilated colon: >7 cm in greatest diameter
- Small Bowel dilation or air-fluid levels may be present
- Mucosal edema or thumbprinting may also be present
- Diagnosis
- Clostridium difficile A and B toxin ELISA
- Preferred over Clostridium difficile culture
- High Test Sensitivity and Test Specificity
- Available within 2 hours of obtaining sample
- Aldeen (2000) Diagn Microbiol Infect Dis 36(4): 211-3
- Endoscopy (Flexible Sigmoidoscopy or Colonoscopy)
- Not recommended in most cases
- May be indicated if diagnosis is unclear
- Findings: Mucosal lesions with pseudomembranes
- Differential Diagnosis
- Antibiotic intolerance (resolves off antibiotics)
- Infectious enteritis
- Acute Gastroenteritis
- Amebic dysentary
- Inflammatory Bowel Disease
- Ischemic Colitis
- Management: General Measures
- Discontinue antibiotic
- Diarrhea resolves in up to 25% of cases with stopping
- If antibiotic required, choose one with lower risk
- Indications to start antibiotics immediately (empiric)
- Older patients
- Multiple comorbid conditions
- Antibiotics can not be discontinued
- Severe disease
- Persistent Diarrhea
- Dysentary (fever, Leukocytosis)
- Avoid and stop medications that could worsen condition
- Proton Pump Inhibitors
- Opioid
- Antidiarrheal agents
- Do not retest for toxin post-treatment if asymptomatic
- May be positive, but does not require treatment
- Management: Adults
- Metronidazole
- Drug of choice due to low cost and high risk
- However resistance is growing and may approach 30% in some regions
- Dose
- Typical: 500 mg orally every 6-8 hours for 10-14 days
- Lower dose: 250 mg orally q6 hours for 10-14 days
- Parenteral dose: 500 mg IV q8 hours for 10-14 days
- Vancomycin
- Precaution: Only effective for C. Difficile if dosed orally
- Indications
- High risk patients of severe, fulminant disease (with 2 or more of the following risk factors)
- Age over 60 years
- Temperature >38.3 C
- Albumin <2.5
- Leukocytosis with White Blood Cell count >15,000
- Serum Creatinine >50% increase over baseline
- Second line agent to Metronidazole
- Risk of promoting Vancomycin resistance
- Very expensive ($800 per course)
- Inexpensive if pharmacist compounds the intravenous form into oral formulation
- Dose: 125-500 mg orally four times daily for 10-14 days
- Use low dose (125 mg) in most patients
- Consider high dose (500 mg) in severe illness
- Studies suggest 125 mg four times daily is as effective as higher doses
- Management: Child
- Mild to Moderate disease: Metronidazole (Flagyl)
- Metronidazole 7 mg/kg (maximum 500 mg) tid for 7 days
- Severe disease: Vancomycin
- Vancomycin 5 mg/kg (maximum 125 mg) q6 hours x7 days
- Management: Recurrence
- Recurrence risk doubles with each episode
- Initial recurrence risk is 20%
- After third episode, recurrence is virtually assured
- Recurrence risk factors
- Prolonged antibiotic use
- Prolonged hospitalization course
- Diverticulosis
- Multiple comorbid illnesses
- Elderly patients
- Immunocompromised
- Vancomycin taper
- Starting dose 125 mg every 6 hours for 1 week
- Taper to 125 mg every 12 hours for 1 week
- Taper to 125 mg daily for 1 week
- Taper to 125 mg every other day for 1 week
- Taper to 125 mg every third day for 2 weeks
- Probiotics (e.g. Florastor)
- Saccharomyces boulardii (avoid if immunocompromised)
- Dose 250 mg PO bid to tid for 1 month
- Has also been used with Vancomycin 500 mg PO qid
- Fecal transfer
- Healthy donor (e.g. spouse) with normal fecal flora
- Sample typically introduced via rectal enema
- Small volume fecal amount (25 grams) sufficient to reestablish normal flora
- Management: Fulminant disease (high mortality rate)
- Indications
- Intractable colitis, toxic Megacolon or bowel perforation
- Severe Leukocytosis (e.g. White Blood Cell count to 30,000)
- Serum Lactate >5
- Multi-system organ failure or other shock-like state
- Management
- Metronidazole IV 500 mg every 8 hours and
- Vancomycin 500 mg PO qid and
- Vancomycin enema 500 mg in 100 cc NS q6 hours
- Delivered by foley in rectum, 30 cc balloon
- Balloon inflated for 60 minutes after dose
- Colectomy may be indicated in the most severe diseases
- Prognosis: Findings of improvement (assess on day 5)
- Fever resolves within first 2 days
- Diarrhea resolves within first 4 days
- Complications
- Toxic Megacolon
- Bowel perforation
- Dehydration
- Electrolyte abnormality
- Prevention
- Avoid Proton Pump Inhibitors unless absolutely indicated
- Avoid broad-spectrum antibiotic use
- Probiotics may be considered in recurrent cases
- Prevent Clostridium difficile spore spread
- Spores are resistant to Alcohol, antibiotics and antiseptics
- Contact isolation of patient
- Use personal protective gear including gloves
- Practice good hygiene
- Hand washing
- Hand santizers are not effective against Clostridium difficile
- Disinfect surfaces
- Bleach
- Alkaline glutaraldehyde
- Ethylene oxide
- References
- Majoewsky EM:RAP C3 2(4): 3
- Suntharam (2006) First 24 hours, Park Nicollet Lecture
- Jabbar (2003) Prim Care 30(1):63-80
- Kyne (2001) Gastroenterol Clin North Am 30(3):753-77
- Hookman (2009) World J Gastroenterol 15(13): 1554-80
- Schroeder (2005) Am Fam Physician 71(5):921-8